Rally

Shift

Major

Wednesday

<h2 id="key-takeaways">Key Takeaways</h2>
<ul>
 <li>FDA announced it will not pursue enforcement action against certain hemp-derived oral CBD products</li>
 <li>The cannabis sector ETF surged 16% for the week, marking its best performance since December</li>
 <li>Major players including Tilray, Canopy Growth, and Curaleaf experienced significant share price increases Thursday</li>
 <li>The announcement follows President Trump’s executive order from December that moved marijuana to Schedule III classification</li>
 <li>Industry experts note the policy remains limited in scope and falls short of comprehensive regulation</li>
</ul>
<p>Major cannabis companies experienced their most impressive weekly performance of the year following an FDA announcement regarding CBD product enforcement. The regulatory shift propelled leading cannabis stocks significantly higher and positioned the sector for its strongest weekly showing in months.</p>
<p>In a Wednesday correspondence, FDA Commissioner Marty Makary indicated the agency would refrain from enforcing specific sections of the Federal Food, Drug, and Cosmetic Act against hemp-sourced oral products solely due to CBD content. This enforcement discretion extends to items marketed as dietary supplements and products administered under physician supervision.</p>
<p>Cannabidiol, or CBD, represents a non-intoxicating component of cannabis plants. Consumers utilize it for various wellness applications, and it appears in numerous health and lifestyle products.</p>
<p>The cannabis sector’s upward momentum started Tuesday, preceding the White House and FDA’s launch of a four-part meeting series with industry representatives to address CBD compliance and enforcement strategies.</p>
<p>This FDA policy shift complements President Trump’s December executive action, which rescheduled marijuana from Schedule I to Schedule III classification under federal drug regulations. That directive also tasked the FDA, National Institutes of Health, and Centers for Medicare and Medicaid Services with developing pathways to broaden CBD access for therapeutic applications.</p>
<p>Cannabis equities experienced a temporary boost following December’s executive order before retracing gains. The industry continues to grapple with challenges including limited banking services, stock exchange listing restrictions, and interstate trade barriers stemming from federal regulations.</p>
<h2 id="tilray-brands">Tilray Brands</h2>
<p><a href="https://coincentral.com/tilray-brands-tlry-stock-jumps-8-on-record-q3-revenue-beat/" rel="noopener noreferrer nofollow">Tilray</a> emerged as a standout performer during this week’s rally. Shares climbed 6.7% in Thursday’s session alone, positioning it among the sector’s highest by dollar volume. The enterprise conducts research, cultivation, processing, and distribution of medical cannabis throughout numerous nations including Canada, Germany, Australia, and Argentina.</p>
<p><a href="https://knockoutstocks.com/stock/TLRY" rel="noopener noreferrer nofollow"><br><img src="https://knockoutstocks.com/api/stocks/TLRY/embed" alt="TLRY Stock Card"><br> Tilray Brands, Inc., TLRY<br></a></p>
<h2 id="canopy-growth">Canopy Growth</h2>
<p>Canopy Growth advanced 2.6% during Thursday trading. The organization markets cannabis and hemp-based products for recreational and therapeutic purposes across the US, Canada, Germany, and additional global markets. Its operations include the Storz and Bickel division, which manufactures cannabis vaporization devices. Canopy joined Tilray as one of the week’s most actively traded cannabis equities.</p>
<p><a href="https://knockoutstocks.com/stock/CGC" rel="noopener noreferrer nofollow"><br><img src="https://knockoutstocks.com/api/stocks/CGC/embed" alt="CGC Stock Card"><br> Canopy Growth Corporation, CGC<br></a></p>
<h2 id="curaleaf-holdings">Curaleaf Holdings</h2>
<p>Curaleaf delivered the most impressive gains among major cannabis companies Thursday, surging 8.4%. This domestically-focused cannabis enterprise has captured significant investor attention as market participants monitor potential federal policy changes that could enable cross-state commerce for cannabis operations.</p>
<p>The AdvisorShares Pure US Cannabis exchange-traded fund climbed 4.6% Thursday and advanced 16% across the week, tracking toward its strongest weekly gain since December.</p>
<p>An industry expert observed the policy represents a “narrowly scoped” approach that falls short of establishing a comprehensive framework for the wider cannabis marketplace, urging Congressional legislative action.</p>
<p>The FDA conducted its initial stakeholder discussion on CBD policy Wednesday, with three additional sessions planned in the continuing series.</p>
<p>The post <a href="https://blockonomi.com/fda-cbd-policy-shift-triggers-massive-rally-in-cannabis-stocks/" rel="noopener noreferrer nofollow">FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.</p>

FDA CBD Policy Shift Triggers Massive Rally in Cannabis Stocks

Table of Contents

Blockonomi

Other articles published on Apr 3, 2026

Join our free newsletter for daily crypto updates!